Department of Medicine and Aging, and Center of Aging Science and Translational Medicine (CESI-Met), "G. d'Annunzio" University of Chieti-Pescara, Chieti, Italy
Department of Medicine and Aging, and Center of Aging Science and Translational Medicine (CESI-Met), "G. d'Annunzio" University of Chieti-Pescara, Chieti, Italy.
Diabetes Care. 2017 Nov;40(11):1556-1564. doi: 10.2337/dc17-0589. Epub 2017 Sep 14.
Obesity is associated with an increased risk of type 2 diabetes and cardiovascular complications. The risk depends significantly on adipose tissue distribution. Liraglutide, a glucagon-like peptide 1 analog, is associated with weight loss, improved glycemic control, and reduced cardiovascular risk. We determined whether an equal degree of weight loss by liraglutide or lifestyle changes has a different impact on subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT) in obese subjects with prediabetes or early type 2 diabetes.
Sixty-two metformin-treated obese subjects with prediabetes or newly diagnosed type 2 diabetes, were randomized to liraglutide (1.8 mg/day) or lifestyle counseling. Changes in SAT and VAT levels (determined by abdominal MRI), insulin sensitivity (according to the Matsuda index), and β-cell function (β-index) were assessed during a multiple-sampling oral glucose tolerance test; and circulating levels of IGF-I and IGF-II were assessed before and after a comparable weight loss (7% of initial body weight).
After comparable weight loss, achieved by 20 patients per arm, and superimposable glycemic control, as reflected by HbA level ( = 0.60), reduction in VAT was significantly higher in the liraglutide arm than in the lifestyle arm ( = 0.028), in parallel with a greater improvement in β-index ( = 0.021). No differences were observed in SAT reduction ( = 0.64). IGF-II serum levels were significantly increased ( = 0.024) only with liraglutide administration, and the increase in IGF-II levels correlated with both a decrease in VAT (ρ = -0.435, = 0.056) and an increase in the β-index (ρ = 0.55, = 0.012).
Liraglutide effects on visceral obesity and β-cell function might provide a rationale for using this molecule in obese subjects in an early phase of glucose metabolism dysregulation natural history.
肥胖与 2 型糖尿病和心血管并发症风险增加相关。这种风险在很大程度上取决于脂肪组织的分布。利拉鲁肽是一种胰高血糖素样肽 1 类似物,它与体重减轻、血糖控制改善和心血管风险降低有关。我们旨在确定肥胖的前驱糖尿病或早期 2 型糖尿病患者,通过利拉鲁肽或生活方式改变达到同等程度的体重减轻,对皮下脂肪组织(SAT)和内脏脂肪组织(VAT)有何不同的影响。
62 名接受二甲双胍治疗的前驱糖尿病或新诊断的 2 型糖尿病肥胖患者,随机分为利拉鲁肽(1.8mg/天)或生活方式咨询组。在多次采样口服葡萄糖耐量试验期间,通过腹部 MRI 评估 SAT 和 VAT 水平(根据 Matsuda 指数)、胰岛素敏感性(β-index)的变化;并在可比体重减轻(初始体重的 7%)前后评估 IGF-I 和 IGF-II 的循环水平。
在每个治疗组各有 20 名患者实现可比较的体重减轻(=0.60),血糖控制相同(HbA1c 水平)的情况下,与生活方式组相比,利拉鲁肽组 VAT 的减少更为显著(=0.028),同时β-index 也有更大的改善(=0.021)。SAT 的减少没有差异(=0.64)。只有在给予利拉鲁肽时,血清 IGF-II 水平才会显著升高(=0.024),并且 IGF-II 水平的增加与 VAT 的减少(ρ=-0.435,=0.056)和β-index 的增加(ρ=0.55,=0.012)呈负相关。
利拉鲁肽对内脏肥胖和β细胞功能的影响可能为在葡萄糖代谢失调自然史的早期阶段,在肥胖患者中使用这种分子提供了一个理由。